1801.HK Stock — Price, Charts & Analysis

Innovent Biologics, Inc. (1801.HK) has a trailing P/E of 186.18x and a forward P/E of 44.93x. This places 1801.HK in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

1801.HK trades with 186.18x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether 1801.HK looks overvalued or undervalued.

1801.HK's P/E of 186.18x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

1801.HK's trailing EPS is HK$0.55 and forward EPS is HK$2.28.

EPS, or earnings per share, shows how much profit Innovent Biologics, Inc. generated for each share. 1801.HK's trailing EPS is HK$0.55, and investors usually prefer EPS that is positive and growing over time.

Innovent Biologics, Inc. has a market cap of HK$178.27B, making 1801.HK a large-cap stock based on the current market value shown on Worldtickers.

1801.HK's latest stock price on Worldtickers is HK$102.40. The latest move is HK$1.20 or 1.19%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

1801.HK's quote includes a latest price of HK$102.40. The market open is HK$101.80. Previous close is HK$101.20. The intraday range is HK$100.60 to HK$104.00.

1801.HK is up in the latest quote, with a move of HK$1.20 or 1.19%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

1801.HK generated HK$13.04B in trailing revenue. Revenue growth is 29.60%, which helps show whether demand is expanding or slowing.

1801.HK's revenue growth is 29.60%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, 1801.HK shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is HK$813.56M.

Gross margin is 76.66%. Margins show how efficiently Innovent Biologics, Inc. turns revenue into profit.

Innovent Biologics, Inc. carries HK$2.82B and holds HK$18.23B in cash.

1801.HK holds HK$18.23B on its balance sheet.

1801.HK's book value per share is HK$13.00.

Institutions hold 59.53% of 1801.HK shares. Insiders hold 6.24% of shares. Ownership mix helps investors understand how much of Innovent Biologics, Inc. is held by professional investors and company insiders.

1801.HK has 1.74B shares outstanding. Float shares are 1.61B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for 1801.HK, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for 1801.HK is HK$2.28. Revenue growth is 29.60%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

1801.HK's trailing EPS is HK$0.55. Forward EPS is HK$2.28. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

1801.HK is in the Healthcare sector. Its earnings multiple is 186.18x. Its latest displayed growth metric is 29.60%. Compare these figures with sector peers before deciding whether Innovent Biologics, Inc. is stronger or weaker than average.

1801.HK trades at HK$102.40. The stock trades at 186.18x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Innovent Biologics, Inc.'s fundamentals.

1801.HK risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.23, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

1801.HK should be compared with companies in Biotechnology. Its earnings multiple is 186.18x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Innovent Biologics, Inc. (1801.HK) operates in Healthcare, specifically Biotechnology. Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab

1801.HK trades on HKSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

1801.HK stock is priced in HKD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Innovent Biologics, Inc.'s official website listed on Worldtickers is www.innoventbio.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Innovent Biologics, Inc. employs about 7.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Innovent Biologics, Inc. is headquartered in Suzhou, China. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

1801.HK is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

1801.HK has traded between HK$69.55 and HK$109.10 over the past 52 weeks. At HK$102.40, it is 6.14% below the high and 47.23% above the low. The 52-week range helps gauge long-term price momentum.

1801.HK is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is HK$87.22 and its 200-day moving average is HK$85.76.

1801.HK's RSI is 70.02. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a overbought momentum setup.

1801.HK's latest RSI reading is 70.02, which points to overbought momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for 1801.HK is near HK$83.40. Key resistance is near HK$102.30. Breaks above resistance or below support can change the short-term technical setup.

1801.HK's nearest reported support level is HK$83.40. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

1801.HK's nearest reported resistance level is HK$102.30. A breakout above resistance can improve momentum, especially when volume confirms the move.

1801.HK trades about 14.68M shares daily on average. The latest displayed volume is 15.25M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

1801.HK's MACD is 0.54, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

1801.HK is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 70.02 (overbought). MACD is bullish. Nearest support is around HK$83.40. Resistance is around HK$102.30. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is HK$92.57 (9.33% from price). MA50 is HK$87.22 (16.03% from price). MA200 is HK$85.76 (18.00% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. 1801.HK's MA20 is HK$92.57. MA50 is HK$87.22. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

1801.HK's pivot is near HK$99.35. Support is near HK$83.40. Resistance is near HK$102.30. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for 1801.HK is near HK$95.08. These levels help define risk and possible follow-through zones after a breakout or breakdown.

1801.HK's Bollinger range is roughly HK$84.11 to HK$101.02. Band width is near 18.26%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

1801.HK's ATR-based typical daily range is about 4.22%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 15.25M shares. Average volume is about 14.68M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

1801.HK's all-time high shown on Worldtickers is HK$109.10. Its all-time low is HK$14.00. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

1801.HK has a beta of 0.23, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.